Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Toshimasa Ishii

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Clinical Colorectal Cancer

Oncology

Gastroenterology

2017

English

Inferior Oncological Prognosis of Surgery Without Oral Chemotherapy for Stage III Colon Cancer in Clinical Settings

World Journal of Surgical Oncology

Surgery

Oncology

2014

English

Related publications

Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer

Annals of Coloproctology

Gastroenterology

2019

English

Factors Associated With Delayed Time to Adjuvant Chemotherapy in Stage Iii Colon Cancer

Current Oncology

Oncology

2014

English

Comparison of Adverse Events During 5-Fluorouracil Versus 5-Fluorouracil/Oxaliplatin Adjuvant Chemotherapy for Stage III Colon Cancer

English

P-0218 * Timing and Regimens of Adjuvant Therapy for Resected Stage Ii and Iii Colon Cancer

English

Oral UFT (Uracil Plus Futrafur) for Neoadjuvant Chemotherapy of Gastric Cancer

English

Survival Analysis of Adjuvant Chemotherapy With S-1 Plus Cisplatin for Stage III Gastric Cancer

English

Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin

Journal of Clinical Oncology

English

Phase I Clinical Trial of a Peptide Vaccine Combined With Tegafur-Uracil Plus Leucovorin for Treatment of Advanced or Recurrent Colorectal Cancer

English

The Clinical and Economic Benefits of Capecitabine and Tegafur With Uracil in Metastatic Colorectal Cancer

British Journal of Cancer

Cancer Research

Oncology

2006

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Toshimasa Ishii

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Inferior Oncological Prognosis of Surgery Without Oral Chemotherapy for Stage III Colon Cancer in Clinical Settings

Related publications

Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer

Factors Associated With Delayed Time to Adjuvant Chemotherapy in Stage Iii Colon Cancer

Comparison of Adverse Events During 5-Fluorouracil Versus 5-Fluorouracil/Oxaliplatin Adjuvant Chemotherapy for Stage III Colon Cancer

P-0218 * Timing and Regimens of Adjuvant Therapy for Resected Stage Ii and Iii Colon Cancer

Oral UFT (Uracil Plus Futrafur) for Neoadjuvant Chemotherapy of Gastric Cancer

Survival Analysis of Adjuvant Chemotherapy With S-1 Plus Cisplatin for Stage III Gastric Cancer

Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin

Phase I Clinical Trial of a Peptide Vaccine Combined With Tegafur-Uracil Plus Leucovorin for Treatment of Advanced or Recurrent Colorectal Cancer

The Clinical and Economic Benefits of Capecitabine and Tegafur With Uracil in Metastatic Colorectal Cancer